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conducted in Europe. RESULTS: The search identified 25.135 articles, 889 titles 
were included for further screening and 409 abstracts for the article review step. 
A total of 308 abstracts did not meet the inclusion/exclusion criteria, leaving a 
pool of 101 articles for full text evaluation. Overall, 10 systematic reviews were 
identified, with 238 primary studies, 129 conducted in Europe. The sample sizes 
from the included primary studies from Europe revealed 20 to 15.343 patients 
with a mean of 514. Chronic conditions investigated were: heart failure, chronic 
obstructive pulmonary disease, diabetes, and cancer. Of the outcomes more 
frequently studied, integrated care appeared to improve quality of life and 
reduce hospitalization. But often results remained inconclusive. CONCLUSIONS: 
Providing a conclusion across the different chronic conditions is not possible. 
Therefore, only disease specific conclusions can be drawn. Our review suggests 
that integrated care might be advantageous for specified groups of patients, e.g. 
heart failure. Furthermore, it remains unclear which specific component is 
associated with the highest benefit for patients across chronic conditions.  
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OBJECTIVES: For SCD patients, inadequate care during pediatric to adult 
transition may result in increased emergency department (ED) utilization. 
Emergency department reliance (EDR: total ED visits/total ambulatory 
[outpatient+ED] visits) identifies the proportion of ED visits in relation to all 
ambulatory visits. This study aimed at investigating age-related patterns of EDR 
and associated health care costs in SCD patients. METHODS: State Medicaid data 
from Florida, New Jersey, Missouri, Iowa, and Kansas were analyzed. Patients 
with ≥2 SCD diagnoses (ICD-9 282.6x) and ≥1 blood transfusion were included. 
Quarterly rates of EDR and SCD complication-related ED visits as well as health 
care costs were evaluated. Based on published thresholds, high EDR was defined 
as >0.33. Regression analyses were used to assess risk factors for high EDR and 
calculate adjusted costs difference between patients with high versus low EDR. 
RESULTS: A total of 3208 patients were identified; mean (SD) observation period 
was 6.5 (3.2) years. Mean ED visits/quarter increased from 0.76 to 2.23 between 
age 15 and 23, reaching a peak of 2.9 at age 36. The most common SCD 
complication-related ED visits were pain, infection, and pneumonia. EDR rose 
from 0.15 to 0.29 between age 15 and 23, and remained high thereafter. Patients 
were more likely to have high EDR during the post-transition period (≥18 years 
old, odds ratio [OR]: 2.38, p<0.001) and when experiencing an SCD complication 
(OR: 4.18, p<0.001). Patients with high EDR incurred higher inpatient and ED 
costs, resulting in higher total costs (high vs. low EDR, adjusted costs difference, 
OP: -$285; IP: $3,485; ED: $120; Rx: -$91; total: $3,086, p<0.001 for all). 
CONCLUSIONS: Compared to children, SCD patients transitioning to adulthood 
relied more on ED for their care and those with high EDR incurred higher health 
care costs, highlighting the need to improve access to care for transitioning and 
adult SCD patients.  
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OBJECTIVES: Pharmacists are qualified to provide many services that are core to 
integrated care models. Expanding services to diverse patient populations will 
increase pharmacists’ value. This study describes the experience, preliminary 
outcomes and revenue model justification associated with the implementation 
of pharmacist-led care for patients with respiratory disorders. METHODS: 
Medical and billing record review was performed on patients with respiratory 
symptoms referred to the pharmacist from May 2011 to September 2012 within a 
community-based, medical home, primary care practice. Patients referred were 
those with respiratory symptoms in which the physician sought objective lung 
function data and additional support to assist in properly diagnosing and 
treating the patient. Pharmacist interventions included collection of a detailed 
pulmonary and medication history, spirometry, and on applicable patients, dis-
ease state education, medication care plans and device education, and smoking 
cessation. Outcomes described included quality and results of spirometry 
testing, pharmacist recommendations, recommendations for specialist care and 
payment for services. RESULTS: Thirty-four patients (76.5% female; mean 
age=49.6±17.6) were seen by the pharmacist and assessed by spirometry. 
Spirometry met American Thoracic Society quality measures in 82.5% of tests 
with the following results: 64.7% normal, obstruction (8.8% mild, 14.7% moderate, 
2.9% severe), and 8.8% probable restriction. Pharmacist recommendations that 
were implemented included the use of short-acting-beta-agonists (23.5%), 
corticosteroids (20.6%), anti-cholinergics (14.7%), and long-acting-beta-agonists 
(11.8%). Smoking cessation was recommended for 11.8% of patients and 44.1% 
received specialist referrals. The mean overall payment for the services provided 
at these visits was $144.43±36.34. CONCLUSIONS: Pharmacist involvement in the 
care of patients with respiratory disorders provided valuable, quality lung 
function data and care plan recommendations to physicians and education to 
patients. These preliminary results support the pharmacist expanding their role 
in the medical home by providing physician/patient care services, including 
spirometry, to patients with respiratory disorders from both a clinical and 
economic perspective.  
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OBJECTIVES: To review the literature published within the last decade related to 
drug-related problems and medication errors in Sub-Saharan Africa. This article 
provides a discussion on pharmaceutical care, with a focus on economic 
outcomes. METHODS: A search using Medline, Embase was conducted over the 
timeframe January 2002–December 2012 using key words such as: Sub-Saharan 
Africa, medication errors, economics, and pharmaceutical care. The abstract 
and/or full text of each article was reviewed. RESULTS: Twenty studies were 
identified for review. The most common problems in the pharmacy system were 
improper labeling, counterfeit drugs, lack of patient education, and inadequate 
drug distribution. The lack of electronic medical records and payment systems 
prevent the assessment of clinical cost outcomes. In a study conducted by the 
University of Benin, of 1500 pharmacists, 93% reported that they would be willing 
to participate in “any training program to enable them to practice pharma-
ceutical care.” There is a lack of pharmacists able to provide pharmaceutical care 
as defined as the direct, responsible provision of medication-related care 
designed to achieve definite outcomes. The shortage of pharmacists is due to 
few training institutions, migration, inadequate pay and poor working 
conditions. Specifically, 25% of the world’s global burden of disease is in Sub 
Saharan Africa, while this area comprises 3% of the world’s health workers. 
These factors contribute to an increase in medication errors. CONCLUSIONS: 
Sub-Saharan Africa lacks the necessary governmental regulation to ensure a 
decrease in medication errors. The government may consider streamlining their 
drug distribution system through the enforcement of regulations and the use of 
information technology in the health care delivery system. Additional studies are 
needed to examine economic outcomes. Several studies provide information on 
cost effectiveness and quality of life, but these studies are specific to the 
HIV/AIDS population.  
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OBJECTIVES: Health care fraud is a long-standing problem, accounting for $75 
billion in 2009. Congress amended the False Claims Act (FCA) in 1986 to allow qui 
tam relators (“whistleblowers”) to receive up to 30% of anti-fraud recoveries. 
Most studies investigate health care fraud involving the pharmaceutical 
industry, so it has not been possible to contextualize fraud involving health care 
sectors other than the pharmaceutical industry. Herein, we review all recently 
concluded major federal health care fraud investigations. METHODS: All cases 
involved health care corporations and federal FCA. Data were collected from 
Lexis/Nexis News (search terms: “Health care fraud”, “False Claims Act” and “Qui 
tam”), the Taxpayers against Fraud and the DOJ websites (2006-2011). Only cases 
with recoveries over $5 million (“major cases”) were included. Data were 
abstracted on allegations, financial settlements, occupations of and payments to 
qui tam relators. Cases are reported separately as qui tam- versus non-qui tam-
initiated to document whether the Congressional intent to encourage 
whistleblowing achieved its intended goal. RESULTS: Between 2006 and 2011, 123 
major qui tam health care FCA cases concluded, totaling $15.7 billion in 
recoveries (mean recovery: $128 million). Billing fraud, kickbacks, off-label 
marketing, and marketing unsafe pharmaceuticals were the most commonly 
implicated activities. Pharmaceutical manufacturers accounted for 31% of, and 
$11.3 billion (70%) in recoveries among qui tam relator cases. Also, 52 non-qui 
tam cases closed in this 5-year period, totaling $3.7 billion in recoveries (mean 
recovery: $71 million). Implicated activities included fraudulent billing, 
inappropriate financial relationships, off-label marketing, or marketing unsafe 
pharmaceuticals. CONCLUSIONS: In conclusion, federal investigations of fraud 
and abuse involving health care are increasing in both depth and breadth,  
and qui tam relators have an important role in detecting important fraud and 
abuse.  
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OBJECTIVES: The Patient Protection and Affordable Care Act will expand the 
eligibility of the Medicaid program to millions of Americans in 2014. Utilizing 
more generic drugs and setting appropriate pharmacy reimbursement rates 
could result in substantial savings to the Medicaid program. This study assessed 
2011 state-level, fee-for-service Medicaid generic and brand drug utilization and 
expenditures, and pharmacy reimbursement rates. METHODS: Medicaid fee-for-
service outpatient pharmacy utilization and expenditures, and reimbursement 
rates (ingredient cost and dispensing fees) for the year 2011 were extracted from 
state-level data provided from the Centers for Medicare and Medicaid Services. 
Descriptive analyses were performed for all variables in the data set. Linear 
regression analysis was performed to assess the relationship between ingredient 
cost, dispensing fees and drug utilization. The significance level for variables was 
0.05. RESULTS: Fee-for-service Medicaid expenditures (n=46 states) reached $27.8 
billion with drug utilization accounting for 173.4 million claims in 2011. Generic 
expenditures represented 17.3% of total expenditures (range=10.3%-29.2%) and 
